Literature DB >> 18056649

The impact of follicular lymphoma on health-related quality of life.

R Pettengell1, C Donatti, P Hoskin, C Poynton, P J Kettle, B Hancock, S Johnson, M J S Dyer, S Rule, M Walker, D Wild.   

Abstract

BACKGROUND: The purpose of this study was to determine whether there was a relationship between disease activity and health functioning, as measured by a range of patient-reported outcome (PRO) measures in patients with follicular lymphoma (FL). PATIENTS AND METHODS: A total of 222 patients with FL were recruited from eight sites across the UK and they completed a number of PRO measures. The participants were analyzed across five disease states: 'active disease-newly diagnosed', 'active disease-relapsed', 'partial response', 'complete response' and 'disease free'. The relationship between these disease states and their level of health functioning was assessed as well as the relationship between being 'on' or 'off' chemotherapy and disease state.
RESULTS: In terms of health-related quality of life (HRQoL), participants in the relapsed category had the lowest mean physical well-being, emotional well-being, functional well-being and social well-being score. In a regression analysis, the 'active disease-relapsed' group acted as a significant predictor for each PRO variable. In addition, the remission group acted as a significant predictor of high anxiety scores as measured by the Hospital Anxiety and Depression Scale.
CONCLUSION: The results of this study demonstrate that various aspects of patient-reported health outcomes differ according to disease state in patients with FL. For those patients who have relapsed, they are more likely to experience worse HRQoL and other patient-reported health outcomes than patients newly diagnosed, in partial or complete remission or when completely disease free.

Entities:  

Mesh:

Year:  2007        PMID: 18056649     DOI: 10.1093/annonc/mdm543

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  22 in total

1.  A high level of fatigue among long-term survivors of non-Hodgkin's lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands.

Authors:  Simone Oerlemans; Floortje Mols; Djamila E Issa; J H F M Pruijt; Wim G Peters; Marnix Lybeert; Wobbe Zijlstra; Jan Willem W Coebergh; Lonneke V van de Poll-Franse
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

Review 2.  Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review.

Authors:  Philipp W P Auweiler; Dirk Müller; Stephanie Stock; Andreas Gerber
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

Review 3.  Quality of life domains among non-Hodgkin lymphoma survivors: an integrative literature review.

Authors:  Ashley Leak; Deborah K Mayer; Sophia Smith
Journal:  Leuk Lymphoma       Date:  2011-05-03

4.  Coping with non-Hodgkin's lymphoma: a qualitative study of patient perceptions and supportive care needs whilst undergoing chemotherapy.

Authors:  Daren Chircop; Josianne Scerri
Journal:  Support Care Cancer       Date:  2017-02-23       Impact factor: 3.603

5.  A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index.

Authors:  Fay J Hlubocky; Kimberly Webster; Jennifer Beaumont; John Cashy; Diane Paul; Amy Abernethy; Karen L Syrjala; Jamie Von Roenn; David Cella
Journal:  Leuk Lymphoma       Date:  2013-02-07

6.  Assessing the impact of cancer among Dutch non-Hodgkin lymphoma survivors compared with their American counterparts: a cross-national study.

Authors:  Simone Oerlemans; Sophia K Smith; Catherine M Crespi; Sheryl Zimmerman; Lonneke V van de Poll-Franse; Patricia A Ganz
Journal:  Psychooncology       Date:  2012-07-26       Impact factor: 3.894

7.  Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation.

Authors:  Mark S Walker; Edward J Stepanski; Carolina Reyes; Sacha Satram-Hoang; Arthur C Houts; Lee S Schwartzberg
Journal:  Ther Adv Hematol       Date:  2011-06

8.  The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry.

Authors:  Simone Oerlemans; Floortje Mols; Marten R Nijziel; Wobbe P Zijlstra; Jan Willem W Coebergh; Lonneke V van de Poll-Franse
Journal:  J Cancer Surviv       Date:  2014-05-13       Impact factor: 4.442

9.  Quality of Life is Similar between Long-term Survivors of Indolent and Aggressive Non-Hodgkin Lymphoma.

Authors:  Anne W Beaven; Greg Samsa; Sheryl Zimmerman; Sophia K Smith
Journal:  Cancer Invest       Date:  2016-07-05       Impact factor: 2.176

10.  A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma.

Authors:  R Marcus; R Aultman; F Jost
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.